The medical device sales playbook is being rewritten in real time. Procedures once confined to hospital operating rooms are migrating to outpatient centers at an accelerating clip, upending the territory maps and physician relationships that field reps have relied on for decades.
MedScout, an Austin startup betting that AI can help sales teams adapt faster, just raised $10 million to prove it.
The growth round, led by Atlanta-based Fulcrum Equity Partners with backing from LiveOak Venture Partners and Stage 2 Capital, arrives roughly 19 months after MedScout's $15 million Series A—and at a moment when the Centers for Medicare & Medicaid Services has added 547 procedures to its ambulatory surgery center list. The regulatory shift, finalized in the 2026 Outpatient Prospective Payment System rule, is scrambling established sales strategies across the medtech industry.
"The landscape is being reshaped by site-of-care shifts and increasing complexity," said Skylar Talley, MedScout's CEO and co-founder, in a statement accompanying the announcement in late February. It's the kind of market turbulence that either sinks incumbents or creates openings for nimbler players.
MedScout is wagering on the latter.
An AI Layer for Territory Planning
The company's core product taps into medical claims data spanning more than 330 million patients—Medicare and commercial payer records updated monthly—to help device reps identify high-value accounts and map referral networks. Think of it as turning sprawling, opaque healthcare data into something actionable for a surgical implant rep trying to figure out which orthopedic surgeon to visit next.
Enterprise revenue has tripled since the Series A closed in July 2024, MedScout says, while monthly active sales reps on the platform jumped 135%. Those are impressive figures, though the company hasn't disclosed absolute numbers or customer counts beyond naming clients like Tactile Medical, SI-BONE, Pulmonx, and Paragon 28.
The recent launch of "Strategies"—a suite of AI agents released to customers in late 2025—seems to be driving engagement. In January alone, customers deployed 81% more unique agents month-over-month. The agents translate broad commercial strategies into territory-specific, prioritized account lists that field reps can act on immediately. Less spreadsheet wrangling, more face time with surgeons.
Perhaps more than anything, the timing is what stands out. Medtech sales has historically been a relationship business, driven by in-person interactions and deep clinical expertise. But as procedures scatter across new care sites and reimbursement models evolve, the old playbook feels increasingly inadequate.
Fulcrum Doubles Down
Philip Lewis, a partner at Fulcrum who joined MedScout's board during the Series A, framed the new investment as "doubling down" on the company's momentum and product differentiation. Fulcrum closed its fourth fund at $275 million back in 2021, with a focus on healthcare IT and B2B SaaS—squarely in MedScout's wheelhouse.
The growth round brings MedScout's total known funding to around $30 million, including a pre-seed round, a $5 million seed in 2023, the Series A, and now this $10 million extension. For a company that LinkedIn pegs at between 11 and 50 employees, that's a substantial war chest.
MedScout plans to plow the fresh capital into expanding its AI capabilities and supporting its enterprise customer base. The competitive landscape includes players like Definitive Healthcare's Carevoyance solution and Sorcero MedTech, though the market for AI-driven sales intelligence in medtech remains relatively nascent.
The real question is whether MedScout can scale fast enough to capitalize on the regulatory disruption before larger incumbents catch up—or before the market adjusts and the urgency fades. For now, at least, the company seems to have momentum. And in a sector where site-of-care shifts are upending decades of sales convention, momentum might be everything.
